A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Dec. 18, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30, 2018. Highlights from the third quarter...
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. 18, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional...
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 -- In a release issued under the same headline earlier today by Delcath Systems, Inc. (OTCQB: DCTH), please note the first sentence of the first paragraph should read:...
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the...
PHP Therapy in ICC Treatment Shows Promise in Retrospective Analysis NEW YORK, Oct. 04, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a...
NEW YORK, Sept. 27, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subscription period of its previously announced rights offering....
Positive Results Observed in Study Endpoints Comparable to Endpoints in Delcath Registration Trial NEW YORK, Sept. 26, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
NEW YORK, Sept. 24, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic...
NEW YORK, Sept. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights...